Metadatos
Mostrar el registro completo del ítemCompartir este ítem
PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
CUNHA, Anthony![](/themes/Mirage2//images/PERSO.svg)
Institut des Maladies Neurodégénératives [Bordeaux] [IMN]
Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
Leer más >
![cc](/themes/Mirage2//images/orcid_icon.png)
Institut des Maladies Neurodégénératives [Bordeaux] [IMN]
Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
CUNHA, Anthony![](/themes/Mirage2//images/PERSO.svg)
Institut des Maladies Neurodégénératives [Bordeaux] [IMN]
Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
< Leer menos
![cc](/themes/Mirage2//images/orcid_icon.png)
Institut des Maladies Neurodégénératives [Bordeaux] [IMN]
Acides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
Idioma
EN
Article de revue
Este ítem está publicado en
Pharmaceutics. 2021-07-08, vol. 13, n° 7
Resumen en inglés
Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for ...Leer más >
Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).< Leer menos
Palabras clave en inglés
PLGA nanoparticles
Neurodegenerative diseases
Drug delivery
Central nervous system
Neuroprotective drugs